Clinical Trials
Localized Sarcoma
A Phase III study comparing preoperative intensity-modulated radiotherapy vs postoperative intensity-modulated radiotherapy for soft tissue sarcomas of the trunk and extremities. Open study
Investigator: Dr. Nader Khaouam
For more information, contact:
Janie Barry 514-252-3400 ext. 4428
This email address is being protected from spambots. You need JavaScript enabled to view it.
A study comparing two types of dressings used after surgery for patients with sarcomas of the lower limbs who have been treated with radiation
Investigator: Dr. Marc Isler
For more information, contact:
Janie Barry 514-252-3400 ext. 4428
This email address is being protected from spambots. You need JavaScript enabled to view it.
Advanced or Metastatic Sarcoma
SUNRISE Study- A study of unesbulin in advanced leiomyosarcoma- Open study
Investigator: Dr. Jonathan Noujaim
For more information, click here
To determine if participation is possible, please contact:
Samara Bloom, Clinical Research Coordinator
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 514 252-3400 ext. 6244 Fax: 514 252-1463
Dedifferentiated Liposarcoma
BRIGHTLINE-1 Study- A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Open study
Investigator: Dr. Jonathan Noujaim
For more information, click here
To determine if participation is possible, please contact:
Samara Bloom, Clinical Research Coordinator
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 514 252-3400 ext. 6244 Fax: 514 252-1463
INTRIGUE Study- A Phase III, multicenter, open-label, randomized, interventional study comparing DCC-2618 to sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. Closed study
Investigator: Dr. Jonathan Noujaim
For more information, click here
Synovial Sarcoma and Myxoid Liposarcoma
IGNYTE-ESO Study- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO). Closed study
Investigator: Dr. Jonathan Noujaim
For more information, click here
ZENTYH-ESO Study- Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors. Closed study
Investigator: Dr. Jonathan Noujaim
For more information, click here